Home  /  Resource Library  /  Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma

Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma

Results of a trial investigating pembrolizumab combined with chemotherapy fortreatment of relapsed Hodgkin lymphoma.